ORIC — ORIC Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $403.05m
- $147.09m
- 40
- 25
- 21
- 18
Annual cashflow statement for ORIC Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -73.7 | -78.7 | -89.1 | -101 | -128 |
| Depreciation | |||||
| Non-Cash Items | 25.4 | 14.2 | 13.5 | 9.08 | 12.1 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.04 | 4.07 | -0.445 | 4.9 | 1.97 |
| Change in Prepaid Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Cash from Operating Activities | -45.3 | -59.5 | -75.1 | -85.7 | -113 |
| Capital Expenditures | -0.667 | -0.939 | -2.08 | -0.849 | -1.19 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | -215 | 159 | -107 | -42.6 | 23.3 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -216 | 158 | -109 | -43.4 | 22.1 |
| Financing Cash Flow Items | -21.2 | -1.85 | -0.399 | -0.227 | -0.168 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Cash from Financing Activities | 251 | 49.1 | 25.2 | 85.7 | 127 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | -10.7 | 148 | -159 | -43.4 | 36 |